NCL foundation announces today that together with the biotechnology Company Evotec AG it supports a three-year PhD programme for research into juvenile neuronal ceroid lipofuscinosis (NCL). Under scientific supervision by Dr Guido Hermey (Hamburg University), the PhD programme will be based in the facilities and laboratories of Evotec AG. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/ncl-foundation-together-with-evotec-and-hamburg-university-explores-new-paths-in-juvenile-ncl-5738